Quimioterapia como tratamiento del cáncer de ovario en el segundo y tercer trimestre de embarazo

Abstract

BACKGROUND: Ovarian cancer is the abnormal growth of cells in tissues. It is the fifth most common tumor diagnosed during pregnancy; it is estimated that 1 in every 1,000 pregnancies is complicated by cancer. In pregnant women, the administration of chemotherapy drugs is classified as category D during pregnancy. GENERAL OBJECTIVE: To describe chemotherapy as a treatment for ovarian cancer in the second and third trimesters of pregnancy. METHODOLOGY: Bibliographic review. Thirty articles published in the last five years, in English and Spanish, were analyzed. Health Sciences Descriptors (DeCS) such as Pregnancy, Ovarian Neoplasms, Therapeutics, Pregnancy Trimester, Second, Pregnancy Trimester, First, and Drug Therapy were used; together with Boolean operators, inclusion criteria within the search for the selection and subsequent analysis of the results. CONCLUSIONS: Compared to the first trimester, there was a low incidence of fetal malformations and maternal complications when chemotherapy was administered during the second and third trimesters of pregnancy. However, it is associated with low birth weight, preterm delivery, and spontaneous abortion, so it should be managed cautiously. The combination of carboplatin and paclitaxel should be used in patients with epithelial ovarian cancer, and the combination of bleomycin, etoposide, and cisplatin in non-epithelial ovarian cancer